Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients?

Nephrology

Volumn 19, Issue 4, 2014, Pages 244-250

  Prasad, Narayan ^a   Gurjer, Desraj ^a   Bhadauria, Dharmender ^a   Gupta, Amit ^a   Srivastava, Aneesh ^a   Kaul, Anupama ^a   Jaiswal, Akhilesh ^a   Yadav, Brijesh ^a   Yadav, Subhash ^a   Sharma, Raj K ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

basiliximab induction; new onset diabetes after transplantation; renal transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; GLUCOSE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; GLUCOSE BLOOD LEVEL; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; KIDNEY ALLOGRAFT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ACUTE DISEASE; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; EPIDEMIOLOGY; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; IMMUNOLOGY; INCIDENCE; INDIA; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INDIA; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896971274     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12209     Document Type: Article

References (35)

1. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM,. Post transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001; 59: 732-737.
2. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ,. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 2003; 3: 178-185.
3. Boudreaux JP, McHugh L, Canafax DM, etal. The impact of cyclosporine and combination immunosuppression on the incidence of post transplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376-381.
4. Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM,. Post-transplant diabetes in kidney transplant recipients. Am. J. Nephrol. 1985; 5: 196-202.
5. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM,. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin. Transplant. 2001; 15: 89-94.
6. Miles AM, Sumrani N, Horowitz R, etal. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380-384.
7. Roth D, Milgrom M, Esquenazi V, Fuller L, Burke G, Miller J,. Post-transplant hyperglycemia: Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47: 278-281.
8. Reisaeter AV, Hartmann A,. Risk factors and incidence of post-transplant diabetes mellitus. Transplant. Proc. 2001; 33: 8S-18S.
9. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC,. Association of hepatitis C with post-transplant diabetes in renal transplant patients on tacrolimus. J. Am. Soc. Nephrol. 2002; 13: 1374-1380.
10. Hjelmesaeth J, Sagedal S, Hartmann A, etal. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550-1556.
11. Sumrani NB, Delaney V, Ding ZK, etal. Diabetes mellitus after renal transplantation in the cyclosporine era: An analysis of risk factors. Transplantation 1991; 51: 343-347.
12. Arner P, Gunnarsson R, Blomdahl S, Groth CG,. Some characteristics of steroid diabetes: A study in renal-transplant recipients receiving high dose corticosteroid therapy. Diabetes Care 1983; 6: 23-25.
13. David DS, Cheigh JS, Braun DW Jr, Fotino M, Stenzel KH, Rubin AL,. HLA-A28 and steroid-induced diabetes in renal transplant patients. JAMA 1980; 243: 532-533.
14. Drachenberg CB, Klassen DK, Weir MR, etal. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402.
15. Knoll GA, Bell RC,. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: Meta-analysis of randomized trials. BMJ 1999; 318: 1104-1107.
16. Mayer AD, Dmitrewski J, Squifflet JP, etal. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443.
17. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS,. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
18. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J,. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782.
19. Vincenti F, Friman S, Scheuermann E, etal. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 2007; 7: 1506-1514.
20. Valderhaug TG, Hjelmesaeth J, Rollag H, etal. Reduced incidence of new-onset post transplantation diabetes mellitus during the last decade. Transplantation 2007; 84: 1125-1130.
21. Tang Q, Adams JY, Penaranda C, etal. Central role of a defective interleukin-2 production in triggering islet autoimmune destruction. Immunity 2008; 28: 687-697.
22. MaigaHulme MA, Wasserfall CH, Atkinson MA, Brusko TM,. Central role for interleukin-2 in type 1 diabetes. Diabetes 2012; 61: 14-22.
23. Morran MP, Omenn GS, Pietropaolo M,. Immunology and genetics of type 1 diabetes. Mt. Sinai J. Med. 2008; 75: 314-327.
24. Brusko T, Bluestone J,. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur. J. Immunol. 2008; 38: 931-934.
25. Setoguchi R, Hori S, Takahashi T, Sakaguchi S,. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005; 201: 723-735.
26. Baan CC, van der Mast BJ, Klepper M, etal. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110-117.
27. Bluestone JA, Liu W, Yabu JM, etal. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am. J. Transplant. 2008; 8: 2086-2096.
28. Bayés B, Pastor MC, Lauzurica R, Granada ML, Salinas I, Romero R,. Do Anti-CD25 monoclonal antibodies potentiate post transplant diabetes mellitus? Transplant. Proc. 2007; 39: 2248-2250.
29. Aasebo W, Midtvedt K, Valderhaug TG, etal. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol. Dial. Transplant. 2010; 25: 1289-1293.
30. Alberti KG, Zimmet PZ,. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998; 15: 539-553.
31. Wang Z, Shi BY, Qian YY, etal. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin. Exp. Immunol. 2009; 155: 496-503.
32. Gutierrez-Ramos JC, Andreu JL, Revilla Y, Viñuela E, Martinez C,. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 1990; 346 (6281): 271-274.
33. Mathew JT, Rao M, Job V, Ratnaswamy S, Jacob CK,. Post-transplant hyperglycaemia: A study of risk factors. Nephrol. Dial. Transplant. 2003; 18: 164-171.
34. Chakkera HA, Mandarino LJ,. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation 2013; 95: 647-652.
35. Webster AC, Woodrofe RC, Taylor RS, Chapman JR, Craig JC,. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomized trial data. BMJ 2005; 331: 810-821.